Menu Close Call 1-800-CEDARS-1 toggle search form Close
Michael R. Freeman, PhD

Michael R. Freeman, PhD

Research
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Michael R. Freeman, PhD
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

Michael R. Freeman, PhD

Research
No patient rating & comments. Why?
  • The doctor practices in an office or specialty that we currently do not survey.
  • The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Michael R. Freeman, PhD

Michael R. Freeman, PhD

Research
Back to Top

Languages

  • English,

Gender

Male

Experience

Specialties

Area in which a healthcare provider is highly trained and often board certified.

1

  • Research

Programs

Cedars-Sinai clinical programs this provider is part of:

3

Research Areas

The research of Michael Freeman, PhD, focuses on urogenital tract physiology, with a primary focus on cancer progression to lethal disease. Prostate cancer is an area of strong emphasis. Freeman also has interest and substantial publication history in molecular studies of bladder cancer, breast cancer, smooth muscle regulation and dysfunction, and interstitial cystitis/pelvic pain syndrome.

Titles

  • Ben Maltz Chair, Cancer Therapeutics
  • Professor, Biomedical Sciences
  • Director, Division of Cancer Biology and Therapeutics Research in the Department of Biomedical Sciences
  • Professor, Surgery
  • Vice Chair, Research
  • Co-Director, Cancer Biology Program

Achievements

  • 5

    Awards and Honors

  • 5

    Publications

Awards and Honors

  • Distinguished Mentor Award, American Urological Association Foundation
  • President, Society for Basic Urologic Research
  • Associate Editor: American Journal of Pathology
  • John K. Lattimer Award
  • MERIT Award, National Institutes of Health

Publications

A full list of this provider’s research publications can be found on their research profile or PubMed.

  • Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR, Pyne S, Agostini M, Freeman MR, Loda M. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene. 2013 Mar 28;32(13):1660-1669.
  • Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012 Mar 15;11(6):1123-1130.
  • Kim J, Di Vizio D, Kim TK, Kim J, Kim M, Pelton K, Clinton SK, Hai T, Hwang D, Solomon KR, Freeman MR. The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS One. 2012;7(7):e39448.
  • Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 2012 Aug;4(8):743-760
  • Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012 Nov;181(5):1573-1584.